ATE304355T1 - Pharmazeutische zusammensetzungen, enthaltend pyridin- oder pyrimidin-derivate, zur hemmung der produktion und sekretion von cytokinen - Google Patents

Pharmazeutische zusammensetzungen, enthaltend pyridin- oder pyrimidin-derivate, zur hemmung der produktion und sekretion von cytokinen

Info

Publication number: ATE304355T1
Authority: AT; Austria
Prior art keywords: pharmaceutical compositions; secretion; diseases; treating; cytokine production
Prior art date: 1999-04-20

Application number

AT00926142T

Other languages

English (en)

Inventor

Merouane Bencherif

Original Assignee

Targacept Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-04-20

Filing date

2000-04-20

Publication date

2005-09-15

2000-04-20 Application filed by Targacept Inc filed Critical Targacept Inc

2005-09-15 Application granted granted Critical

2005-09-15 Publication of ATE304355T1 publication Critical patent/ATE304355T1/de

Links

239000008194 pharmaceutical composition Substances 0.000 title abstract 5
230000028327 secretion Effects 0.000 title abstract 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 2
102000004127 Cytokines Human genes 0.000 title 1
108090000695 Cytokines Proteins 0.000 title 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
230000002401 inhibitory effect Effects 0.000 title 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title 1
229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
-1 amine compounds Chemical class 0.000 abstract 3
230000016396 cytokine production Effects 0.000 abstract 3
125000003118 aryl group Chemical group 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
208000037765 diseases and disorders Diseases 0.000 abstract 2
208000030507 AIDS Diseases 0.000 abstract 1
208000023275 Autoimmune disease Diseases 0.000 abstract 1
206010006895 Cachexia Diseases 0.000 abstract 1
206010061218 Inflammation Diseases 0.000 abstract 1
208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
206010003246 arthritis Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000004064 dysfunction Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
230000001613 neoplastic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Epidemiology (AREA)
Tropical Medicine & Parasitology (AREA)
Oncology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
AIDS & HIV (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Obesity (AREA)
Diabetes (AREA)
Dermatology (AREA)
Nutrition Science (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT00926142T 1999-04-20 2000-04-20 Pharmazeutische zusammensetzungen, enthaltend pyridin- oder pyrimidin-derivate, zur hemmung der produktion und sekretion von cytokinen ATE304355T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/295,181 US6166048A (en)	1999-04-20	1999-04-20	Pharmaceutical compositions for inhibition of cytokine production and secretion
PCT/US2000/010551 WO2000062767A2 (en)	1999-04-20	2000-04-20	Pharmaceutical compositions containing pyridine or pyrimidine derivates for inhibition of cytokine production and secretion

Publications (1)

Publication Number	Publication Date
ATE304355T1 true ATE304355T1 (de)	2005-09-15

Family

ID=23136585

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00926142T ATE304355T1 (de)	1999-04-20	2000-04-20	Pharmazeutische zusammensetzungen, enthaltend pyridin- oder pyrimidin-derivate, zur hemmung der produktion und sekretion von cytokinen

Country Status (13)

Country	Link
US (2)	US6166048A (de)
EP (1)	EP1171127B1 (de)
JP (1)	JP2002542188A (de)
KR (1)	KR100816898B1 (de)
AT (1)	ATE304355T1 (de)
AU (1)	AU4471900A (de)
BR (1)	BR0009869A (de)
CA (1)	CA2370206C (de)
DE (1)	DE60022637T2 (de)
DK (1)	DK1171127T3 (de)
ES (1)	ES2251995T3 (de)
MX (1)	MXPA01010635A (de)
WO (1)	WO2000062767A2 (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020052497A1 (en) *	2000-03-09	2002-05-02	Targacept, Inc.	Compounds capable of activating cholinergic receptors
US6979695B2 (en) *	1996-04-23	2005-12-27	Targacept, Inc.	Compounds capable of activating cholinergic receptors
EP1068186A2 (de)	1998-04-02	2001-01-17	Targacept, Inc.	3-pyridylalkoxyamine oder aryloxyalkylamine derivate als cholinergische agonisten
US7790757B2 (en) *	1998-06-16	2010-09-07	Targacept, Inc.	Compounds capable of activating cholinergic receptors
WO2000071520A2 (en) *	1999-05-24	2000-11-30	Targacept, Inc.	Aryl substituted alkylamines capable of activating nicotinic cholinergic receptors
US20010031771A1 (en)	1999-05-24	2001-10-18	Gary Maurice Dull	Pharmaceutical compositions and methods for use
DE19956786A1 (de) *	1999-11-25	2001-05-31	Basf Ag	Verfahren zur Herstellung optisch aktiver Amine
US6656958B2 (en)	2000-02-02	2003-12-02	Abbott Laboratories	Substituted pyridine compounds useful for controlling chemical synaptic transmission
US20010034357A1 (en) *	2000-02-02	2001-10-25	Nan-Horng Lin	Substituted pyridine compounds useful for controlling chemical synaptic transmission
US8914114B2 (en)	2000-05-23	2014-12-16	The Feinstein Institute For Medical Research	Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US6610713B2 (en)	2000-05-23	2003-08-26	North Shore - Long Island Jewish Research Institute	Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
GB2381750A (en) *	2001-10-10	2003-05-14	Inspire Pharmaceuticals Inc	Treatment for enhancing joint lubrication
US7442546B2 (en) *	2002-03-15	2008-10-28	The Regents Of The University Of Michigan	Method of modulating inflammatory response
US6987027B2 (en)	2002-08-23	2006-01-17	The Regents Of The University Of California	Microscale vacuum tube device and method for making same
US6864162B2 (en) *	2002-08-23	2005-03-08	Samsung Electronics Co., Ltd.	Article comprising gated field emission structures with centralized nanowires and method for making the same
CA2560756A1 (en)	2004-03-25	2005-10-06	The Feinstein Institute For Medical Research	Methods and devices for reducing bleed time using vagus nerve stimulation
US10912712B2 (en)	2004-03-25	2021-02-09	The Feinstein Institutes For Medical Research	Treatment of bleeding by non-invasive stimulation
AU2004318159B8 (en) *	2004-04-02	2011-05-26	Sahajanand Medical Technologies Private Limited	Polymer-based stent assembly
DE602005025020D1 (de)	2004-12-27	2011-01-05	The Feinstein Inst Medical Res	Behandlung von entzündlichen erkrankungen durch el
US11207518B2 (en)	2004-12-27	2021-12-28	The Feinstein Institutes For Medical Research	Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
CA2877177C (en)	2007-01-29	2018-05-22	Simon Fraser University	Transvascular nerve stimulation apparatus and methods
US8391970B2 (en)	2007-08-27	2013-03-05	The Feinstein Institute For Medical Research	Devices and methods for inhibiting granulocyte activation by neural stimulation
US20090239901A1 (en) *	2008-03-19	2009-09-24	Merouane Bencherif	Method and compositions for treatment of cerebral malaria
US9662490B2 (en)	2008-03-31	2017-05-30	The Feinstein Institute For Medical Research	Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
US9211409B2 (en)	2008-03-31	2015-12-15	The Feinstein Institute For Medical Research	Methods and systems for reducing inflammation by neuromodulation of T-cell activity
ES2452484T3 (es)	2008-11-18	2014-04-01	Setpoint Medical Corporation	Dispositivos para optimizar la colocación de electrodos para la estimulación antiinflamatoria
TW201031664A (en)	2009-01-26	2010-09-01	Targacept Inc	Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
US9211410B2 (en)	2009-05-01	2015-12-15	Setpoint Medical Corporation	Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8996116B2 (en)	2009-10-30	2015-03-31	Setpoint Medical Corporation	Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
CN102573986B (zh)	2009-06-09	2016-01-20	赛博恩特医疗器械公司	用于无导线刺激器的具有袋部的神经封套
US9833621B2 (en)	2011-09-23	2017-12-05	Setpoint Medical Corporation	Modulation of sirtuins by vagus nerve stimulation
WO2014169145A1 (en)	2013-04-10	2014-10-16	Setpoint Medical Corporation	Closed-loop vagus nerve stimulation
CN102821814B (zh)	2009-12-23	2015-07-15	赛博恩特医疗器械公司	用于治疗慢性炎症的神经刺激设备和系统
US20110268809A1 (en)	2010-04-28	2011-11-03	Paul Andrew Brinkley	Nicotine-Containing Pharmaceutical Compositions
US20110274628A1 (en)	2010-05-07	2011-11-10	Borschke August J	Nicotine-containing pharmaceutical compositions
WO2012154865A2 (en)	2011-05-09	2012-11-15	Setpoint Medical Corporation	Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US12172017B2 (en)	2011-05-09	2024-12-24	Setpoint Medical Corporation	Vagus nerve stimulation to treat neurodegenerative disorders
US20130078307A1 (en)	2011-09-22	2013-03-28	Niconovum Usa, Inc.	Nicotine-containing pharmaceutical composition
US9907748B2 (en)	2011-10-21	2018-03-06	Niconovum Usa, Inc.	Excipients for nicotine-containing therapeutic compositions
US9763928B2 (en)	2012-02-10	2017-09-19	Niconovum Usa, Inc.	Multi-layer nicotine-containing pharmaceutical composition
CN107126622A (zh)	2012-03-05	2017-09-05	西蒙·弗雷瑟大学	神经刺激系统
US9572983B2 (en)	2012-03-26	2017-02-21	Setpoint Medical Corporation	Devices and methods for modulation of bone erosion
EP4233953A3 (de)	2012-06-21	2023-11-01	Lungpacer Medical Inc.	Transvaskuläre membranschrittmachersysteme
RU2514007C1 (ru) *	2012-10-04	2014-04-27	Государственное научное учреждение Северо-Кавказский зональный научно-исследовательский ветеринарный институт (ГНУ СКЗНИВИ) Российской академии сельскохозяйственных наук	Протистоцидная активность 2-(4,5-дихлоримидазолил-1)-5 нитропиридина
US20140255452A1 (en)	2013-03-11	2014-09-11	Niconovum Usa, Inc.	Method and apparatus for differentiating oral pouch products
CN105873630B (zh)	2013-11-22	2020-01-03	隆佩瑟尔医疗公司	用于通过经血管神经刺激辅助呼吸的装置和方法
EP3096835B1 (de)	2014-01-21	2019-08-07	Lungpacer Medical Inc.	Systeme zur optimierung von multi-elektroden-nervenstimulation
US11311725B2 (en)	2014-10-24	2022-04-26	Setpoint Medical Corporation	Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
WO2016126807A1 (en)	2015-02-03	2016-08-11	Setpoint Medical Corporation	Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US20170165252A1 (en)	2015-12-10	2017-06-15	Niconovum Usa Inc.	Protein-enriched therapeutic composition
US10596367B2 (en)	2016-01-13	2020-03-24	Setpoint Medical Corporation	Systems and methods for establishing a nerve block
US11471681B2 (en)	2016-01-20	2022-10-18	Setpoint Medical Corporation	Batteryless implantable microstimulators
CN108882885A (zh)	2016-01-20	2018-11-23	赛博恩特医疗器械公司	迷走神经刺激的控制
WO2017127758A1 (en)	2016-01-20	2017-07-27	Setpoint Medical Corporation	Implantable microstimulators and inductive charging systems
US10583304B2 (en)	2016-01-25	2020-03-10	Setpoint Medical Corporation	Implantable neurostimulator having power control and thermal regulation and methods of use
CN107473982B (zh) *	2016-06-08	2020-01-14	四川大学	端位取代高烯丙基胺衍生物及其制备方法和用途
US10293164B2 (en)	2017-05-26	2019-05-21	Lungpacer Medical Inc.	Apparatus and methods for assisted breathing by transvascular nerve stimulation
EP4115942B1 (de)	2017-06-30	2024-04-24	Lungpacer Medical Inc.	System zur vorbeugung, abschwächung und/oder behandlung von kognitiven läsionen
US10195429B1 (en)	2017-08-02	2019-02-05	Lungpacer Medical Inc.	Systems and methods for intravascular catheter positioning and/or nerve stimulation
US10940308B2 (en)	2017-08-04	2021-03-09	Lungpacer Medical Inc.	Systems and methods for trans-esophageal sympathetic ganglion recruitment
WO2019036470A1 (en)	2017-08-14	2019-02-21	Setpoint Medical Corporation	TESTING TEST FOR STIMULATION OF NERVE WAVE
US20190175908A1 (en)	2017-12-11	2019-06-13	Lungpacer Medical Inc.	Systems and methods for strengthening a respiratory muscle
DK3807260T3 (da)	2018-06-15	2024-10-14	Reynolds Tobacco Co R	Oprensning af nikotin
US11260229B2 (en)	2018-09-25	2022-03-01	The Feinstein Institutes For Medical Research	Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
WO2020097331A1 (en)	2018-11-08	2020-05-14	Lungpacer Medical Inc.	Stimulation systems and related user interfaces
US12343535B2 (en)	2019-04-12	2025-07-01	Setpoint Medical Corporation	Vagus nerve stimulation to treat neurodegenerative disorders
EP3968932B1 (de)	2019-05-16	2025-07-02	Lungpacer Medical Inc.	Systeme zur erfassung und stimulation
JP7550461B2 (ja)	2019-06-12	2024-09-13	ラングペーサーメディカルインコーポレイテッド	医療刺激システムのための回路
JP2023512447A (ja)	2020-01-13	2023-03-27	ザファインスタインインスティチューツフォーメディカルリサーチ	脾臓への高密度集束超音波刺激による出血及び出血性疾患の治療
US11938324B2 (en)	2020-05-21	2024-03-26	The Feinstein Institutes For Medical Research	Systems and methods for vagus nerve stimulation
US12444497B2 (en)	2021-05-17	2025-10-14	Setpoint Medical Corporation	Neurostimulation parameter authentication and expiration system for neurostimulation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5212188A (en) *	1992-03-02	1993-05-18	R. J. Reynolds Tabacco Company	Method for treatment of neurodegenerative diseases
US5852041A (en) *	1993-04-07	1998-12-22	Sibia Neurosciences, Inc.	Substituted pyridines useful as modulators of acethylcholine receptors
AU2394795A (en) *	1994-04-28	1995-11-29	Du Pont Merck Pharmaceutical Company, The	Hydroxamic acid and amino acid derivatives and their use as anti-arthritic agents
US5597919A (en) *	1995-01-06	1997-01-28	Dull; Gary M.	Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5616707A (en) *	1995-01-06	1997-04-01	Crooks; Peter A.	Compounds which are useful for prevention and treatment of central nervous system disorders
US5604231A (en) *	1995-01-06	1997-02-18	Smith; Carr J.	Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5583140A (en) *	1995-05-17	1996-12-10	Bencherif; Merouane	Pharmaceutical compositions for the treatment of central nervous system disorders
US5616716A (en) *	1996-01-06	1997-04-01	Dull; Gary M.	(3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
US5663356A (en) *	1996-04-23	1997-09-02	Ruecroft; Graham	Method for preparation of aryl substituted alefinic secondary amino compounds
ES2318856T4 (es) *	1996-04-23	2010-03-03	Targacept, Inc.	Composiciones farmaceuticas para la prevencion y el tratamiento de trastornos del sistema nervioso central.
ZA9711092B (en) *	1996-12-11	1999-07-22	Smithkline Beecham Corp	Novel compounds.
US5811442A (en) *	1997-02-21	1998-09-22	Bencherif; Merouane	Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow
US5861423A (en) *	1997-02-21	1999-01-19	Caldwell; William Scott	Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
AU7132998A (en) *	1997-04-24	1998-11-13	Ortho-Mcneil Corporation, Inc.	Substituted pyrrolopyridines useful in the treatment of inflammatory diseases

1999
- 1999-04-20 US US09/295,181 patent/US6166048A/en not_active Expired - Fee Related
2000
- 2000-04-20 CA CA2370206A patent/CA2370206C/en not_active Expired - Fee Related
- 2000-04-20 BR BR0009869-8A patent/BR0009869A/pt not_active IP Right Cessation
- 2000-04-20 AU AU44719/00A patent/AU4471900A/en not_active Abandoned
- 2000-04-20 AT AT00926142T patent/ATE304355T1/de active
- 2000-04-20 EP EP00926142A patent/EP1171127B1/de not_active Expired - Lifetime
- 2000-04-20 WO PCT/US2000/010551 patent/WO2000062767A2/en not_active Ceased
- 2000-04-20 DK DK00926142T patent/DK1171127T3/da active
- 2000-04-20 MX MXPA01010635A patent/MXPA01010635A/es active IP Right Grant
- 2000-04-20 ES ES00926142T patent/ES2251995T3/es not_active Expired - Lifetime
- 2000-04-20 DE DE60022637T patent/DE60022637T2/de not_active Expired - Lifetime
- 2000-04-20 JP JP2000611904A patent/JP2002542188A/ja active Pending
- 2000-04-20 KR KR1020017013390A patent/KR100816898B1/ko not_active Expired - Fee Related
- 2000-09-06 US US09/656,284 patent/US6489349B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO2000062767A3 (en)	2001-03-08
AU4471900A (en)	2000-11-02
DK1171127T3 (da)	2005-10-03
KR100816898B1 (ko)	2008-03-26
DE60022637T2 (de)	2006-06-29
CA2370206C (en)	2011-09-27
CA2370206A1 (en)	2000-10-26
BR0009869A (pt)	2002-03-26
EP1171127B1 (de)	2005-09-14
US6489349B1 (en)	2002-12-03
KR20020002434A (ko)	2002-01-09
JP2002542188A (ja)	2002-12-10
US6166048A (en)	2000-12-26
EP1171127A2 (de)	2002-01-16
WO2000062767A2 (en)	2000-10-26
MXPA01010635A (es)	2002-03-14
DE60022637D1 (de)	2005-10-20
ES2251995T3 (es)	2006-05-16

Legal Events

Date

Code

Title

Description

2006-06-15

UEP

Publication of translation of european patent specification

Ref document number: 1171127

Country of ref document: EP

Publication	Publication Date	Title
DE60022637D1 (de)	2005-10-20	Pharmazeutische zusammensetzungen, enthaltend pyridin- oder pyrimidin-derivate, zur hemmung der produktion und sekretion von cytokinen
BG105712A (en)	2002-06-28	SUBSTITUTED 2-ARYL-3-(HETEROARYL)-IMIDAZO[1,2-a] PYRIMIDINES, AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS
PL1699800T3 (pl)	2010-07-30	Bicykliczne heterocykliczne inhibitory kinazy p-38
DK1539166T3 (da)	2008-10-20	Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
MXPA05013075A (es)	2006-03-17	Inhibidores de p-38 basados en heterociclo de 5 miembros.
EA200600064A1 (ru)	2006-08-25	Производные тиенопиридона как ингибиторы киназ
BG106406A (en)	2002-09-30	Pyrimidine-2,4,6-trione metalloproteinase inhibitors
MXPA05013824A (es)	2006-02-28	Inhibidores de quinasa p38 basados en heterociclos de 5 miembros.
YU97902A (sh)	2006-05-25	Ciklopentanoindoli, smeše koje sadrže takva jedinjenja i metodi lečenja
EP1034164A4 (de)	2001-07-11	Beta-alanin-derivate als zell-adhäsions-inhibitoren
DE60118003D1 (de)	2006-05-11	Harnstoffderivate und ihre verwendung
DE60028358D1 (de)	2006-07-06	Hmg1 antagonisten zur behandlung von entzündungen
NO20043290L (no)	2004-09-22	Deazapuriner og anvendelse av slike
GB0209891D0 (en)	2002-06-05	Novel compounds
HRP20080467A2 (hr)	2008-11-30	Derivati 5-beta-sapogenina i pseudosapogenina te njihova uporaba u liječenju demencije
BR9910025A (pt)	2000-12-26	Mesilato de n-(3-etinilfenilamino)-6,7-bis(2-metoxietóxi)-4-quinazo linamina desidratado e monoidratado
ATE272628T1 (de)	2004-08-15	Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
ATE403433T1 (de)	2008-08-15	Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen
EP1244452A4 (de)	2003-01-15	Urotensin-ii rezeptorantagonisten
SI1492773T1 (sl)	2009-06-30	4-(heterociklil)-benzensulfoksiminske spojine za zdravljenje vnetja
SE0102858D0 (sv)	2001-08-27	N-type calcium channel antagonists for the treatment of pain
WO2002068476A3 (en)	2003-08-07	Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders
NZ530587A (en)	2004-12-24	Diazacycloalkanes as oxytocin agonists
DK1196442T3 (da)	2006-05-08	VGF-polypeptider og fremgangsmåder til behandling af VGF-relaterede lidelser
ATE381568T1 (de)	2008-01-15	Pyrano(2,3-c)imidazo(1,2-a)pyridin-derivate zur behandlung von gastrointestinalen erkrankungen